SCHEMBL6791395

SCHEMBL6791395

CC(C)N1CCCc2cc(/C=C3\SC(=S)N(CCCS(=O)(=O)O)C3=O)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
CTNNB1 P35222 2/20 0.43
TCF4 P15884 1/20 0.43
MAPT P10636 4/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
MYC P01106 1/20 0.41
MAX P61244 1/20 0.41
GPR35 Q9HC97 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
NCOA3 Q9Y6Q9 2/20 0.41
XBP1 P17861 1/20 0.41
MAPK1 P28482 1/20 0.41
POLB P06746 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6791405 1.00 MEN1 (0.43) MEN1KMT2ACTNNB1TCF4MAPT
SCHEMBL6797642 0.78 ALDH1A1 (0.45) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL6797635 0.78 ALDH1A1 (0.45) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL6482725 0.73 CTNNB1 (0.57) MEN1KMT2ACTNNB1TCF4MAPT
SCHEMBL6482730 0.73 CTNNB1 (0.57) MEN1KMT2ACTNNB1TCF4MAPT
SCHEMBL6475342 0.72 FABP4 (0.54) MEN1KMT2ACTNNB1TCF4MAPT
SCHEMBL6475339 0.72 FABP4 (0.54) MEN1KMT2ACTNNB1TCF4MAPT
SCHEMBL6476411 0.71 PTPN12 (0.53) MEN1KMT2AMAPTALDH1A1TDP1
SCHEMBL6476416 0.71 PTPN12 (0.53) MEN1KMT2AMAPTALDH1A1TDP1
SCHEMBL13170354 0.70 PTPN12 (0.57) MEN1KMT2AMAPTPTPN12PTPN22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 MEN1 360/4885KMT2A 4348/4885CTNNB1 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.